摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1苄基-4-异丙氨基哌啶-4-羧酸胺 | 1031-36-3

中文名称
1苄基-4-异丙氨基哌啶-4-羧酸胺
中文别名
——
英文名称
1-benzyl-4-(isopropylamino)piperidine-4-carboxamide
英文别名
1-benzyl-4-isopropylamino-4-piperidinecarboxamide;1-Benzyl-4-carbamoyl-4-isopropylamino-piperidin;1-benzyl-4-(propan-2-ylamino)piperidine-4-carboxamide
1苄基-4-异丙氨基哌啶-4-羧酸胺化学式
CAS
1031-36-3
化学式
C16H25N3O
mdl
——
分子量
275.394
InChiKey
MSWWMXGLWBQMNG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    117.8-120.4 °C
  • 沸点:
    438.7±45.0 °C(Predicted)
  • 密度:
    1.09±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    58.4
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090

SDS

SDS:dc85d0ec93dd6842987017974215791a
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Cannabinoid receptor ligands and uses thereof
    申请人:Pfizer Inc
    公开号:US20040248881A1
    公开(公告)日:2004-12-09
    Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1
    化合物的化学式(I)或(II),其作为大麻素受体配体并在治疗与动物体内大麻素受体介导相关疾病中的用途被描述在此。
  • [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
    申请人:BIOAXONE THERAPEUTIQUE INC
    公开号:WO2005080394A1
    公开(公告)日:2005-09-01
    Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
    提供了由结构I表示的取代哌啶化合物,其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部,可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶,并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长,从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长,并在需要Rho激酶抑制的疾病治疗中发挥作用。
  • 4-Substituted piperidine derivatives
    申请人:McKerracher Lisa
    公开号:US20050272751A1
    公开(公告)日:2005-12-08
    Substituted piperidine compounds represented by the structure I are provided, wherein each of R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g , R 1h , R 2 , R 2A , R 3 , R 4 , A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
    提供了由结构式I表示的取代哌啶化合物,其中R1a、R1b、R1c、R1d、R1e、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n的定义如规范中所述。结构式I的取代哌啶化合物可以渗透或穿过神经细胞膜进入神经细胞内部,可以抑制哺乳动物神经细胞中发现的细胞内Rho激酶酶,并可用于修复哺乳动物中心和周围神经系统中的受损神经。这些化合物可以诱导哺乳动物神经细胞的轴突再生或生长,从而诱导受损或患病的神经组织再生。这些化合物还可作为Rho激酶酶拮抗剂,在治疗涉及Rho激酶酶的疾病状态中发现其他用途。含有这些取代哌啶化合物的制药组合物可用于促进神经轴突生长,并用于治疗需要Rho激酶抑制的疾病。
  • CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
    申请人:Carpino A. Philip
    公开号:US20070213334A1
    公开(公告)日:2007-09-13
    Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    本文描述了化学式(I)或(II)的化合物,其作为大麻素受体配体并且在动物中治疗与大麻素受体介导有关的疾病方面的用途。
  • ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF
    申请人:Shipps, JR. Gerald W.
    公开号:US20120328691A1
    公开(公告)日:2012-12-27
    The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
    本发明涉及式(I)的新型苯胺哌嗪衍生物,包含该苯胺哌嗪衍生物的组合物,以及使用该苯胺哌嗪衍生物治疗或预防增生性疾病、癌症、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病、真菌感染或与蛋白激酶活性相关的疾病的方法。
查看更多